Press Releases

Date Title
September 21, 2021 Progenity to Participate in 11th Annual Partnership Opportunities in Drug Delivery Conference
SAN DIEGO, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced today that the company will participate in the 11 th  annual Partnership Opportunities in Drug Delivery (PODD) Conference, October 28-29, 2021 in Boston.
September 14, 2021 Progenity Announces Patent Granted by USPTO for its Preeclampsia Rule-Out Test
SAN DIEGO, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,112,403 for assessment of preeclampsia using assays for free and dissociated
September 3, 2021 Progenity to Participate in Two Upcoming Investor Conferences
SAN DIEGO, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced that the company will participate in two upcoming virtual investor conferences: A pre-recorded presentation at H.C. Wainwright’s 23rd Annual Global Investment
August 24, 2021 Progenity Announces Closing of $40 Million Underwritten Public Offering
SAN DIEGO, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (Nasdaq: PROG), an innovative biotechnology company, today announced the closing of its previously announced underwritten public offering of 40,000,000 shares of its common stock and warrants to purchase up to 40,000,000
August 19, 2021 Progenity Announces Pricing of $40 Million Public Offering of Common Stock and Warrants
SAN DIEGO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (Nasdaq: PROG), an innovative biotechnology company, today announced the pricing of its previously announced underwritten public offering of 40,000,000 shares of its common stock and warrants to purchase up to 40,000,000
August 19, 2021 Progenity Announces Proposed Underwritten Public Offering of Common Stock and Warrants
SAN DIEGO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (Nasdaq: PROG), an innovative biotechnology company, announced today that it intends to offer and sell, subject to market and other conditions, shares of its common stock and warrants to purchase shares of its common stock
August 12, 2021 Progenity Provides Corporate Update and Reports Second Quarter 2021 Financial Results
Announced successful completion of the validation study PRO-104 for the Preecludia™  rule out test for preeclampsia and achievement of the primary endpoint of the study protocol Recently achieved promising results with the prototype autonomous Oral Biotherapeutics Delivery System in a single oral
August 5, 2021 Progenity to Report Second Quarter 2021 Financial Results and Provide Corporate Update
SAN DIEGO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), an innovative biotechnology company, today announced that it will report second quarter 2021 financial results on Thursday, August 12, 2021 after the close of financial markets.
July 29, 2021 Progenity Announces Successful Completion of Clinical Validation Study and Achievement of the Primary Endpoint for its Preeclampsia Rule-Out Test
The company’s Preecludia™ test performed strongly in a broad, intended-use population SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced today successful completion of the validation study for its Preecludia™ rule-out test for
June 30, 2021 Progenity Announces Appointment of Surbhi Sarna to its Board of Directors
SAN DIEGO, June 30, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced the appointment of Surbhi Sarna to its board of directors effective July 1, 2021. Ms. Surbhi’s medical device experience and her focus on development of strategic partnerships
Displaying 1 - 10 of 86